AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02242396
Drug: Telmisartan hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00954785
Drug: Diclofenac 50 mg tds
RxNorm normalized name: diclofenac sodium 50 MG
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
Trial: NCT00954785
Drug: Etoricoxib 120 mg mane
RxNorm normalized name: etoricoxib 120 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
Trial: NCT01965925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For every randomly assigned 2 subjects receiving active drug, 1 will be randomly assigned to receive placebo for 8 weeks.
Trial: NCT00004867
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02009618
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04193202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered twice daily as a placebo oral tablet matching gefapixant
Trial: NCT01602315
Drug: BYL719 as film-coated (FC) whole tablets
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral alpha-specific PI3K inhibitor
Trial: NCT01602315
Drug: BYL719 drink suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral alpha-specific PI3K inhibitor
Trial: NCT01984398
Drug: 12.5 mg Androxal Formulation A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 12.5 mg Androxal formulation A
Trial: NCT01984398
Drug: 12.5 mg Androxal Formulation B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 12.5 mg Androxal Formulation B
Trial: NCT01984398
Drug: 25 mg Androxal Formulation A
RxNorm normalized name: testosterone 20.25 MG/ACTUAT [Androgel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 25 mg Androxal formulation A
Trial: NCT01984398
Drug: 25 mg Androxal Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 25 mg Androxal formulation B
Trial: NCT00800007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
Trial: NCT03846843
Drug: OCR-002 IR Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCR-002 3 gram immediate release (IR) tablet for oral administration
Trial: NCT03846843
Drug: OCR-002 Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCR-002 5 gram solution for oral administration
Trial: NCT03846843
Drug: OCR-002 IV Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCR-002 5 gram solution for intravenous (IV ) administration
Trial: NCT00803894
Drug: MK0752
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
Trial: NCT00803894
Drug: Comparator: MK0752.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
Trial: NCT00803894
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose placebo capsules: there will be a 7-day washout period between treatments.
Trial: NCT04485403
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg/day ( 2 x 400mg) for 3 weeks in women with a bodyweight \<70 kg, and a dose of 1200 mg/day (3x400mg) in women weighing\> 70kg. The effects of treatment will be compared on the basis of changes in the hormonal profile and inflammatory markers, as well as the clinical assessment of the patient.
Trial: NCT03197493
Drug: carbidopa-levodopa 25-100 mg
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
Trial: NCT01834820
Drug: Epinephrine and Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01834820
Drug: Hypertonic Saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01834820
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00373789
Drug: Botulinum Toxin A, bladder detrusor muscle injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 U provided as a total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices.
Trial: NCT00373789
Drug: Vehicle saline as placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices
Trial: NCT00856401
Drug: PTH1-84 in parent study
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily injection of rhPTH(1-84); 25, 50 75, or 100mcg in parent study. In ADD-ON study, there is no intervention, only testing.
Trial: NCT00942682
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally once daily in the morning
Trial: NCT00335244
Drug: Placebo of intravenous L-citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of intravenous L-citrulline
Trial: NCT03524391
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Care group had standard chemotherapy regimens
Trial: NCT02496884
Drug: DS-5565
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-5565 7.5 mg tablet for oral use
Trial: NCT02496884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet for oral use to match DS-5565 7.5 mg tablet
Trial: NCT02019719
Drug: GSK1278863
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
Trial: NCT02019719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated tablets of GSK1278863 matching placebo for oral administration.
Trial: NCT02076373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. administration
Trial: NCT02031276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for risankizumab administered by IV infusion
Trial: NCT01148810
Drug: BAF312
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01148810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01136239
Drug: N-acetycysteine (600mg twice daily)
RxNorm normalized name: N-6022
DrugBank: N-6022 (DB12206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetycysteine (600mg twice daily) for one year
Trial: NCT01136239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (600mg twice daily)
Trial: NCT01523821
Drug: Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]
RxNorm normalized name: alpha 1-proteinase inhibitor, human 1 MG [Glassia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha 1-Proteinase Inhibitor, Human 1 MG \[Glassia\] at various levels over different days
Trial: NCT01586442
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months
Trial: NCT01586442
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks
Trial: NCT06195228
Drug: Other Targets: precise treatment based on the target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced thyroid cancer patients who had other treatment targets not included above
Trial: NCT00246259
Drug: Oral Antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
Trial: NCT04342065
Drug: Celecoxib capsules
RxNorm normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
Trial: NCT00814931
Drug: CXB722
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg CXB722 oral liquid suspension twice a day for 8 days
Trial: NCT00814931
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching oral liquid suspension placebo twice a day for 8 days
Trial: NCT01397019
Drug: Oxaliplatin, irinotecan, 5-FU & leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors
Trial: NCT05072405
Drug: Simvastatin 20 mg (Zocor®, MSD)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg given once alone, once with green tea extract and once with soy isoflavones extract.
Trial: NCT05072405
Drug: rosuvastatin 10 mg (Crestor®, Astra Zeneca)
RxNorm normalized name: rosuvastatin calcium 10 MG [Crestor]
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin 10 mg are given once alone, once with green tea extract and once with soy isoflavones extract.
Trial: NCT00385021
Drug: 5-Fluorouracil, leucovorin, oxaliplatin, avastin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01552343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.
Trial: NCT04976465
Drug: Anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~   Other Names: HCQ~3. Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.~   Other Names: Asp~4. Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.~Other Names: LMWH
Trial: NCT00070447
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00070447
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02981290
Drug: Renodapt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.
Trial: NCT02981290
Drug: Mycept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
Trial: NCT02981290
Drug: Cellmune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
Trial: NCT01009294
Drug: Chronic Corticosteroid Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrollment was stratified to ensure evaluation of approximately half of the participants were receiving chronic corticosteroid therapy and approximately half of participants were not receiving chronic corticosteroid therapy. Therefore, 3 out of 6 participants were receiving chronic corticosteriod therapy. For the participants receiving chronic corticosteriod therapy, a stable corticosteriod regimen was to be maintained during the study.
Trial: NCT03247400
Drug: 1% simvastatin-acid sodium salt ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% simvastatin-acid sodium salt ointment applied onto a predefined limb
Trial: NCT03247400
Drug: 1% atorvastatin calcium salt ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% atorvastatin calcium salt ointment applied onto a predefined limb
Trial: NCT00393822
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one bolus IV injection at 120 μg/kg/day of matched placebo
Trial: NCT01824602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sugar pills
Trial: NCT05042245
Drug: Ornithine aspartate granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornithine aspartate granules in the experimental arm.
Trial: NCT05042245
Drug: Silymarin capsule
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin capsules in the active comparator arm.
Trial: NCT05042245
Drug: Silymarin capsule simulant
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin capsule simulant in the experimental arm.
Trial: NCT05042245
Drug: Ornithine aspartate granule simulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornithine aspartate granule simulant in the active comparator arm.
Trial: NCT03008512
Drug: Genexol-PM
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02677584
Drug: Prophylactic caffeine citrate
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
Trial: NCT02677584
Drug: Therapeutic caffeine citrate
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
Trial: NCT01615510
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, single administration
Trial: NCT02603575
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
Trial: NCT00839111
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 180 mg/m2,CF 400mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
Trial: NCT03019549
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT01912534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
Trial: NCT02128490
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen tablets
Trial: NCT01434225
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
Trial: NCT03969017
Drug: Nucleoside （acid）analogue (NAs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.
Trial: NCT02348307
Drug: FYU-981, (Oral single dosing)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
Trial: NCT02348307
Drug: Placebo, (Oral single dosing)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the placebo arm receive placebo.
Trial: NCT00565955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive placebo tablets.
Trial: NCT02602509
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03941444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid oral solution
Trial: NCT03874234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.
Trial: NCT00087295
Drug: Depsipeptide
RxNorm normalized name: palmitoyl dipeptide-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depsipeptide wil be given 13 mg/m\^2 through an intravenous (IV) over 4 hours on day 1, 8, and 15 for every 28 days (1 cycle = 28 days) until progression. Patients achieving a complete response (CR) will receive two additional cycles of treatment, and then be removed from protocol treatment.
Trial: NCT03026803
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00559338
Drug: recombinant B-type, natriuretic peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
Trial: NCT00559338
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
Trial: NCT03802721
Drug: [14C]-benzo[a]pyrene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micro-dose (50 ng) (5.4 nCi)
Trial: NCT02976831
Drug: AZD0284
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, concentration: 2 mg/mL and 15 mg/mL
Trial: NCT02976831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching AZD0284 in the form of an oral solution with water.
Trial: NCT00506389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo tablets contained the following excipients: hydroxypropyl cellulose, maize starch (USP name corn starch), magnesium stearate, and lactose monohydrate.
Trial: NCT01057628
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03715465
Drug: Melatonin 0.5 MG
RxNorm normalized name: melatonin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin tablet
Trial: NCT03815292
Drug: MMH-MAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT03815292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT00702624
Drug: placebo-recFSH (follitropin beta)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
Trial: NCT02506777
Drug: Fluoruracil
RxNorm normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02506777
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02506777
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02506777
Drug: melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00469508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg pills taken orally daily for 12 wks
Trial: NCT03561779
Drug: YYD302 2ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YYD302 2ml
Trial: NCT03561779
Drug: Active comparator: Synovian Inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator: Synovian Inj.
Trial: NCT02974361
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02974361
Drug: Ibuprofen-LDH
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02406144
Drug: MLN9708
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04134897
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/m2, bid, per os, days 1-14, 4 cycles